Jazz Pharmaceuticals (JAZZ) PT Raised to $179 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 51c, Raises FY Guidance
November 5, 2019 4:22 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $4.10, $0.51 better than the analyst estimate of $3.59. Revenue for the quarter came in at $538 million versus the consensus estimate of $524.39 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2019 EPS of $15.50-$16.15, versus the consensus of $15.03.... More
